2. Academic Validation
  3. Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling

Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling

  • Am J Pathol. 2014 Jul;184(7):2111-22. doi: 10.1016/j.ajpath.2014.04.002.
Evan R Delgado 1,  Jing Yang 1,  Juhoon So 2,  Stephanie Leimgruber 3,  Michael Kahn 4,  Tohru Ishitani 5,  Donghun Shin 2,  Gabriela Mustata Wilson 6,  Satdarshan P Monga 7
Affiliations

Affiliations

  • 1 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • 2 Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • 3 Department of Pharmacology, University of Virginia, Charlottesville, Virginia, Los Angeles, California.
  • 4 Department of Molecular Pharmacology and Toxicology, School of Pharmacy, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • 5 Division of Cell Regulation Systems, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • 6 Department of Health Services and Health Administration, University of Southern Indiana, Evansville, Indiana. Electronic address: gmwilson@usi.edu.
  • 7 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: smonga@pitt.edu.
PMID: 24819961 DOI: 10.1016/j.ajpath.2014.04.002
Abstract

Hepatocellular carcinoma (HCC), the third most common cause of cancer-related deaths worldwide, lacks effective medical therapy. Large subsets of HCC demonstrate Wnt/β-catenin activation, making this an attractive therapeutic target. We report strategy and characterization of a novel small-molecule inhibitor, ICG-001, known to affect Wnt signaling by disrupting β-catenin-CREB binding protein interactions. We queried the ZINC online database for structural similarity to ICG-001 and identified PMED-1 as the lead compound, with ≥70% similarity to ICG-001. PMED-1 significantly reduced β-catenin activity in hepatoblastoma and several HCC cells, as determined by TOPflash reporter assay, with an IC50 ranging from 4.87 to 32 μmol/L. Although no toxicity was observed in primary human hepatocytes, PMED-1 inhibited Wnt target expression in HCC cells, including those with CTNNB1 mutations, and impaired cell proliferation and viability. PMED-1 treatment decreased β-catenin-CREB binding protein interactions without affecting total β-catenin levels or activity of other common kinases. PMED-1 treatment of Tg(OTM:d2EGFP) zebrafish expressing GFP under the β-catenin/Tcf reporter led to a notable decrease in β-catenin activity. The PMED effect on β-catenin signaling lasted from 12 to 24 hours in vitro and 6 to 15 hours in vivo. Thus, using a rapid and cost-effective computational methodology, we have identified a novel and specific small-molecule inhibitor of Wnt signaling that may have implications for HCC treatment.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-164520
    β-catenin抑制剂
    Wnt
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z